SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Theriva Biologics, Inc. (TOVX) News

Follow Theriva Biologics, Inc. (TOVX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol TOVX Asset equity Sector Markets 90 days 5 Last 0.1203 Updated Nov 02, 2026, 09:22 PM UTC Open live news feed Open TOVX chart & news
M Theriva Sells Ribaxamase Assets to Biossil for $350,000 Upfront Theriva Biologics completed the sale of Ribaxamase-related and certain SYN-006 assets to Biossil Labs for $350,000 upfront, plus potential milestone, royalty and license payments. A related amendment requires Theriva to EQUITY | Nov 02, 2026, 09:22 PM UTC M Theriva Sells SYN-004 Portfolio to Biossil Labs Theriva received $350,000 upfront at closing and is eligible for up to $91 million in additional payments. MNA | Nov 02, 2026, 01:03 PM UTC M Theriva Sells SYN-004 and Related Portfolio to Biossil Labs Theriva received $350,000 upfront at closing and is eligible for up to $91 million in regulatory and sales milestones, plus low single-digit royalties on net product sales. Biossil will assume future development and comm EQUITY | Nov 02, 2026, 01:02 PM UTC L Theriva Biologics, Inc. (TOVX) VIRAGE Phase 2b Results Published; VIRAGE2 Underway Theriva Biologics said VIRAGE Phase 2b data for VCN-01 in metastatic pancreatic cancer were published in Nature Medicine, showing improved OS, PFS and DoR vs SoC. The company has initiated VIRAGE2 to assess more frequent NEWS | Sep 30, 2026, 12:09 PM UTC L Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer -- Data are consistent with an im NEWS | Sep 30, 2026, 12:08 PM UTC M TOVX Starts VIRAGE2 Trial For Metastatic Pancreatic Cancer TOVX begins clinical trial for pancreatic cancer treatment EQUITY | Aug 06, 2026, 12:00 PM UTC